{{cart_num}}
My CartCAS：1256388-51-8
Molecular Formula：C49H54F2N8O6
Molecular Weight：889
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：Light yellow to yellow Solid
Qty：
Size：
| CAS | 1256388-51-8 |
| Name | Ledipasvir |
| Molecular Formula | C49H54F2N8O6 |
| Molecular Weight | 889 |
| Solubility | Soluble in DMSO ≥5mg/mL |
| Purity | ≥98% |
| Appearance | Light yellow to yellow Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| MDL | MFCD25976756 |
| SMILES | CC(C)[C@@H](C(=O)N1CC2(CC2)C[C@H]1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C5(F)F)C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)[C@@H]9[C@H]1CC[C@H](C1)N9C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC |
| InChIKey | VRTWBAAJJOHBQU-KMWAZVGDSA-N |
| InChI | InChI=1S/C49H54F2N8O6/c1-24(2)39(56-46(62)64-5)44(60)58-23-48(15-16-48)21-38(58)42-52-22-37(55-42)28-9-13-32-31-12-8-26(18-33(31)49(50，51)34(32)19-28)27-10-14-35-36(20-27)54-43(53-35)41-29-7-11-30(17-29)59(41)45(61)40(25(3)4)57-47(63)65-6/h8-10，12-14，18-20，22，24-25，29-30，38-41H，7，11，15-17，21，23H2，1-6H3，(H，52，55)(H，53，54)(H，56，62)(H，57，63)/t29-，30+，38-，39-，40-，41-/m0/s1 |
| PubChem CID | 67505836 |
| Target Point | HCV |
| Passage | Anti-infection |
| Background | Ledipasvir is a potent HCV NS5A inhibitor that inhibits GT1a and GT1b replicator M. |
| Biological Activity | Ledipasvir 是丙型肝炎病毒 NS5A 的抑制剂，对基因型 1a 和 1b 复制子的 EC50 分别为 34 pM 和 4 pM。也是一种 SARS-CoV 3CLpro 抑制剂，IC50 为 1.62 μM。[31-] |
| Data Literature Source | [1]. Link JO，et al. Discovery of ledipasvir (GS-5885): a potent，once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem. 2014 Mar 13;57(5):2033-46. doi: 10.1021/jm401499g. Epub 2014 Jan 10. Erratum in: J Med Chem. 2016 Aug 25;59(16):7696. [2]. Hernandez D，et al. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol. 2013 May;57(1):13-8. [3]. Sun Q，et al. Bardoxolone and bardoxolone methyl，two Nrf2 activators in clinical trials，inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212. |
| Unit | Bottle |
| Specification | 5mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
